Dimensional Fund Advisors LP Relmada Therapeutics, Inc. Transaction History

Dimensional Fund Advisors LP

$403 Billion
Q3 2024

A detailed history of Dimensional Fund Advisors LP transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 73,404 shares of RLMD stock, worth $231,956. This represents 0.0% of its overall portfolio holdings.

Number of Shares

73,404

Previous 73,400 0.01%

Holding current value

$231,956

Previous $220,000 7.73%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	BUY	$2.3 - $4.36 $9 - $17	4 Added 0.01%	73,404 $237,000
Q2 2024 Aug 09, 2024	SELL	$2.93 - $4.94 $1,230 - $2,074	-420 Reduced 0.57%	73,400 $220,000
Q3 2023 Nov 09, 2023	SELL	$2.48 - $3.79 $2,313 - $3,536	-933 Reduced 1.25%	73,820 $221,000
Q2 2023 Aug 09, 2023	BUY	$2.22 - $3.54 $42,590 - $67,914	19,185 Added 34.53%	74,753 $183,000
Q1 2023 May 12, 2023	SELL	$2.24 - $4.76 $11,345 - $24,109	-5,065 Reduced 8.35%	55,568 $125,000
Q4 2022 Feb 09, 2023	SELL	$2.17 - $35.84 $300,039 - $4.96 Million	-138,267 Reduced 69.52%	60,633 $211,000
Q3 2022 Nov 10, 2022	SELL	$18.3 - $37.02 $49,538 - $100,213	-2,707 Reduced 1.34%	198,900 $7.36 Million
Q2 2022 Aug 12, 2022	BUY	$16.5 - $30.34 $1.33 Million - $2.45 Million	80,860 Added 66.97%	201,607 $3.83 Million
Q1 2022 May 13, 2022	BUY	$16.72 - $26.99 $931,053 - $1.5 Million	55,685 Added 85.59%	120,747 $3.26 Million
Q4 2021 Feb 09, 2022	BUY	$16.93 - $26.82 $200,755 - $318,031	11,858 Added 22.29%	65,062 $1.47 Million
Q3 2021 Nov 12, 2021	BUY	$21.86 - $34.77 $879,624 - $1.4 Million	40,239 Added 310.37%	53,204 $1.39 Million
Q2 2021 Aug 12, 2021	BUY	$29.55 - $39.15 $383,115 - $507,579	12,965 New	12,965 $415,000

Others Institutions Holding RLMD

# of Institutions

Shares Held

12.3M

Call Options Held

229K

Put Options Held

138K

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $90.4M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.

Account

Dimensional Fund Advisors LP Relmada Therapeutics, Inc. Transaction History